Oral Presentation from Phase 3 FOCUS Trial of CHEMOSAT®

CHEMOSAT®: New data for patients with metastatic ocular melanoma (mOM) Oral Presentation from Phase 3 FOCUS Trial of CHEMOSAT® at the American Society of Clinical Oncology (ASCO) Annual Meeting Wedel, Germany (26.05.2021)  CHEMOSAT® , marketed by medac, is a minimally invasive delivery system for the administration of high-dose chemotherapy directly to the liver while controlling…